Skip to Content

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

Professor Eric Pujade-Lauraine and his team have investigated if patients suffering from ovarian carcinoma who relapse after first line treatment with Olaparib (PARP inhibitor) will benefit of maintenance restarting of the same drug. Results suggest significant improvement in progression free survival, regardless of BRCAm or HRD status.

Get access to the article

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top